Theranexus宣布1b期研究结果,证明与多奈哌齐相比,其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展

2020-01-18 不详 MedSci原创

Theranexus是一家在神经疾病治疗领域的创新型生物制药公司,并且是开发可调节神经元与神经胶质细胞之间相互作用的先驱。最近该公司宣布了在健康受试者中Ib期研究的结果,该研究评估了与阿尔茨海默氏病相关的神经认知障碍标准治疗相比,其候选药物THN201的药理特性。

Theranexus是一家在神经疾病治疗领域的创新型生物制药公司,并且是开发可调节神经元与神经胶质细胞之间相互作用的先驱。最近该公司宣布了在健康受试者中Ib期研究的结果,该研究评估了与阿尔茨海默氏病相关的神经认知障碍标准治疗相比,其候选药物THN201的药理特性。

THN201是多奈哌齐(阿尔茨海默氏病相关神经认知障碍的一线治疗药物)和甲氟喹的组合,甲氟喹已经被批准以低剂量用作调节神经胶质细胞的药物。

结果表明,与多奈哌齐单药治疗相比,THN201的药理作用得以扩展。通过认知药物研究(CDR)的计算评估,THN201作用可实现更高的记忆速度。定量EEG分析报告也证明,与认知活动相关的γ谱带在THN201作用下能量更大。其他测量的药理学终点数据表明THN201和多奈哌齐的作用相似。

此外,有关安全性终点的数据表明,THN201具有与多奈哌齐相似的优异耐受性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1754497, encodeId=89561e54497b8, content=<a href='/topic/show?id=8fd5431e863' target=_blank style='color:#2F92EE;'>#多奈哌齐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43178, encryptionId=8fd5431e863, topicName=多奈哌齐)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c5fb36698279, createdName=shanyongle, createdTime=Thu Jul 16 13:08:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811386, encodeId=e74d1811386f7, content=<a href='/topic/show?id=43628e918e9' target=_blank style='color:#2F92EE;'>#药理学特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87918, encryptionId=43628e918e9, topicName=药理学特性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Sun Jun 28 06:08:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990429, encodeId=4b2119904297c, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Wed Jul 29 01:08:00 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Dec 21 18:08:00 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795675, encodeId=ce601e9567583, content=<a href='/topic/show?id=651a1e401b4' target=_blank style='color:#2F92EE;'>#THN201#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17401, encryptionId=651a1e401b4, topicName=THN201)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sun Jun 14 05:08:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816976, encodeId=855b18169e68e, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Sep 01 19:08:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817999, encodeId=deb8181e99973, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Mar 14 01:08:00 CST 2020, time=2020-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739536, encodeId=a4691e3953618, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Aug 02 14:08:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052421, encodeId=bc6e20524216b, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Feb 13 00:08:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378383, encodeId=edee3e8383b0, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jan 21 22:09:56 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-01-21 wxl882001

    了解一下

    0